Trials / Recruiting
RecruitingNCT05884320
Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To learn if sacituzumab govitecan can help to control salivary gland cancer.
Detailed description
Primary Objectives: * To assess the efficacy of SG in patients with R/M secretory gland carcinomas, specifically ACC (cohort 1) and SDC, adeno-NOS, and MEC (cohort 2) Secondary Objectives: * To estimate the median duration of response (DOR) * To estimate the median progression-free survival (PFS) * To estimate the median overall survival (OS) * To assess safety of SG Tertiary / Exploratory Objectives: * To explore biomarkers that may predict response to therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Govitecan | Given by IV (vein) |
Timeline
- Start date
- 2023-07-27
- Primary completion
- 2028-07-31
- Completion
- 2028-07-31
- First posted
- 2023-06-01
- Last updated
- 2026-03-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05884320. Inclusion in this directory is not an endorsement.